Gene therapy to improve migration of T cells to the tumor site

Methods Mol Biol. 2010:651:103-18. doi: 10.1007/978-1-60761-786-0_7.


One requirement for anti-tumor T cells to be effective is their successful traffic to tumor sites. Trafficking of T cells to lymphoid organs and peripheral tissues is a multistage process. Soluble and tissue-bonded chemokines interacting with chemokine receptors expressed by T lymphocytes certainly play a pivotal role in determining migration under physiologic conditions and during inflammation. Therefore a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express is required. Since chemokine produced by the targeted tumor may not match the subset of chemokine receptors expressed by T cells, gene therapy can be used to force the expression of the specific chemokine receptor by effector T cells so that the anti-tumor activity of adoptively transferred anti-tumor T cells is maximized.

MeSH terms

  • Animals
  • Biological Assay
  • Cell Movement*
  • Genetic Therapy / methods*
  • Humans
  • Immunophenotyping
  • Lymphocyte Activation / immunology
  • Mice
  • Neoplasms / pathology*
  • Neoplasms / therapy*
  • T-Lymphocytes / cytology*
  • T-Lymphocytes / immunology
  • Transduction, Genetic